Table 5

Genes regulated by gefitinib and cetuximab in A431 cells

Gene symbolGefitinib foldCetuximab foldDescription
Cell cycle/DNA replication
PRIM1−3.33−2.32 Primase, polypeptide 1 (49 kd)
CCNH−2.50−2.20 Cyclin H
CCNC−2.43−2.25 Cyclin C
TOP1−2.20−2.40 Topoisomerase (DNA) 1
TOP2A−2.17−2.08 Topoisomerase (DNA) II α (170 kd)
CCNA2−2.16−2.20 Cyclin A2
Cell adhesion
PCDHB5−2.27−2.27 Protocadherin β 5
ITGA6−2.20−2.17 Integrin, α 6
ITGB5−2.12−2.27 Integrin, β 5
EMP1−2−4 Epithelial membrane protein 1
PCDHA102.062.01 Protocadherin α 10
CLDN12.332.24 Claudin 1
PCDHA122.612.15 Protocadherin α 12
CDH12.922.96 Cadherin 1, type 1, E-cadherin (epithelial)
Cell growth
VEGF−3.80−4.65 Vascular endothelial growth factor
LTBP2−2.17−2.32 Latent transforming growth factor β binding protein 2
PDGFA−2.08−2.04 Platelet-derived growth factor α polypeptide
GADD45B2.292.16 Growth arrest and DNA-damage-inducible, β
BST22.422.28 Bone marrow stromal cell antigen 2
IGFBP32.632.50 Insulin-like growth factor binding protein 3
Cell death related
TNFRSF6−2.81−3.70 Tumor necrosis factor receptor superfamily, member 6 (FAS)
TNFSF102.742.44 Tumor necrosis factor receptor (ligand) superfamily member 10 (TRAIL)
Transcription related
BCL3−3.70−2.31 B-cell CLL/lymphoma 3
SIX6−3.22−2.63 Sine oculis homeobox (Drosophila) homolog 6
ZFP37−2.63−2.86 Zinc finger protein homologous to Zfp37 in mouse
MATR3−2.50−2.27 Matrin 3
LRRC2−2.43−2.17 Leucine-rich-repeat-containing 2
PBX2−2.17−2.22 Pre-B-cell leukemia transcription factor 2
TCF6L1−2.04−2.63 Transcription factor 6-like 1 (mitochondrial TF 1-like)
HDAC2−2−2.50 Histone deacetylase 2
XBP1−2.04−2.2 X-box binding protein 1
TRAP952.032.14 Thyroid hormone receptor-associated protein, 95 kd subunit
HDAC7A2.052.37 Histone deacetylase 7A
POU5F12.162.80 POU domain, class 5, transcription factor 1
Signal transduction
NXPH1−2.98−4 Neurexophilin 1
ILRAP−2.50−3.57 Interleukin1 receptor accessory protein
PRKRIR−2.25−2.35 Protein-kinase, interferon-inducible dsrna dependent inhibitor
TEK−2.22−4 TEK tyrosine kinase
MAPK8IP32.032.17 Mitogen-activated protein kinase 8 interacting protein 3
MAP3K102.102.17 Mitogen-activated protein kinase kinase kinase 10
IL1RN2.653.69 Interleukin1 receptor antagonist
ARF5−2.56−3.33 ADP-ribosylation factor 5
ARF12.612.12 ADP-ribosylation factor 1
TUBB5−8.19−7.7 Tubulin, β 5
CAPZA1−2.70−2.56 Capping protein (actin filament), muscle Z-line, α 1
KRT192.374.48 Keratin 19
LYPLA1−2.22−2.7 Lysophospholipase 1
Basic cellular function
TBCE−2.38−2.08 Tubulin-specific chaperone E
VBP1−2.32−2.5 Von Hippel-Lindau binding protein 1
N33−2.22−2.56 Putative prostate cancer tumor suppressor
MAN1−2.12−2.32 Integral inner nuclear membrane protein
Secreted protein
CTSD2.552.69 Cathepsin D (lysosomal aspartyl protease)
SERPINE1−2.70−2.63 Serine (or cysteine) proteinase inhibitor, plasminogen activator inhibitor 1 (PAI-1)
TSSC3−5.2−5.55 Tumor suppressing subtransferable candidate 3
PCANAP1−2.77−3.92 Prostate cancer associated protein 1
P23−2.63−2.86 Unactive progesterone receptor, 23 kd
TSSC12.022.31 Tumor suppressing subtransferable candidate 1
ANXA82.242.03 Annexin A8
SKI2.142.01 V-ski avian sarcoma viral oncogene homolog
  • Note. This table includes the genes found to be ≥2-fold up-regulated or down-regulated in A431 cells treated with gefitinib or cetuximab with respect to untreated tumor cells.